The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- The GLP-1 Paradox in Colorectal Cancer (Medscape)
- The most pressing workforce issues for 103 healthcare leaders (Becker’s Healthcare)
- FDA-cleared GI test detects ‘most likely causes’ of diarrheal syndromes (Healio)
- A path forward: women in gastroenterology (Gastrointestinal Endoscopy)
- 5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)
- Endoluminal Robotics – what it really is (How to Startup in MedTech)
- AI in GI: A Humanist Approach (GI & Endoscopy News)
- Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
